EPO Patents = 5

Forward Citations = 0

Loading Chart...

12 inventors (with patents filed for the assignee):

William Jia (3 out of 3 patents)

Xuexian Bu (2 out of 2 patents)

I-Fang Lee (2 out of 2 patents)

4. Mitchell H Finer (2 out of 6 patents)

5. Luke Evnin (1 out of 3 patents)

6. Christophe Quéva (1 out of 2 patents)

7. Edward Kennedy (1 out of 2 patents)

8. Lorena Lerner (1 out of 2 patents)

9. Dmitry Chouljenko (1 out of 1 patent)

10. Guoyu Liu (1 out of 1 patent)

11. Erica Lee (1 out of 1 patent)

12. Jun Ding (1 out of 1 patent)

13. Zahid Delwar (0 patent)

14. Erica Lee (0 patent)

15. Jun Ding (0 patent)

5 patents: Sort by Forward Citations

1. 12208126 - Oncolytic viral vectors and uses thereof (2025-01-28),

2. 12162919 - Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules (2024-12-10),

3. 11865081 - Oncolytic viral delivery of therapeutic polypeptides (2024-01-09),

4. 11384119 - Compositions and methods for inhibiting CD279 interactions (2022-07-12),

5. 10590169 - Compositions and methods for inhibiting CD279 interactions (2020-03-17),

Virogin Biotech Canada Ltd is a biotechnology company focused on developing innovative oncolytic virus therapies for the treatment of various cancers. Utilizing proprietary virus engineering technologies, Virogin aims to provide effective and safe therapeutic options that enhance the body's immune response to tumors. The company's lead product candidates are being evaluated in clinical trials, with the goal of advancing cancer treatment and improving patient outcomes. Virogin is committed to scientific excellence, patient safety, and bringing novel therapies to market.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

5 Patents

#12 in

#2,752 in

Richmond, Canada

Virogin Biotech Canada Ltd